Medication error at the primary secondary care interface: costs, causes, consequences

Background: Medication error is an important patient safety issue worldwide and results in morbidity, mortality and economic burden. The true cost of medication error is unclear from current evidence. Medication error is particularly common at the primary secondary care interface as patients move between hospital and the community. Developing interventions to reduce medication error (and in particular error at this interface in care) is currently an international priority. Existing interventions, such as medication reconciliation, are often resource intensive. Within healthcare systems, where resources are limited, measures to reduce costs and improve process efficiency are required in addition to optimising patient care. Aim: The overarching aim of this thesis is to examine medication error at the primary secondary care interface in terms of cost, causes and consequences in order to develop a pragmatic intervention to facilitate its reduction. Structure and methods: The Medical Research Council, UK (MRC) guidance on the development and evaluation of complex interventions in healthcare was employed. Existing evidence on the cost of medication error was systematically reviewed and synthesised in a narrative synthesis. A cost per error was extracted and expressed in Euro. A cross-sectional study was conducted. The study examined an existing process of medication reconciliation in terms of factors predicting time burden and associated financial cost. Logistic regression was used to investigate associations between patient characteristics and clinically significant errors and additional time. Cost for additional time was calculated in terms of hospital pharmacist salary. The new evidence generated was used, along with the existing evidence base, to develop a novel intervention aiming to reduce the occurrence of medication error at the primary secondary care interface. The intervention, the PHARMS (Patient Held Active Record of Medication Status) device, is a patient held electronic record used to transmit medication information between primary and secondary care. The intervention was evaluated by a mixed methods feasibility study (non-randomised controlled intervention and a process evaluation of qualitative interviews and non-participant observation). The study was informed by the Consolidated Framework for Implementation Research (CFIR). The occurrence of medication error was compared between groups and factors associated with medication error investigated using negative binomial regression. Thematic analysis of data from semi-structured interviews with key stakeholders was conducted. Results: Systematic review: 16 studies were included in the systematic review. The review identified that medication error is associated with significant economic impact with an associated cost of up to €111,727.08 per error. In view of the limited parameters used to establish economic impact, it was concluded that the true economic burden of medication error may have been underestimated to date. Cross-sectional study: 89 patients were included. Having a personal record of medication at admission (OR 3.30, 95% CI: (1.05 to 10.42), p=0.004) was a significant predictor of additional time. No significant associations were found between the occurrence of clinically significant error and additional time (p>0.05). The most common reason for additional time was clarifying issues pertaining to communication of medication information from primary care. Projected annual five year costs for the mean additional time of 3.75 minutes of the study were €1.8-1.9 million. Feasibility study: 102 patients were included (Intervention n=41, Control n=63). Total error number was lower in the intervention group Median=1 (0,3 IQR) than the control group Median=8 (4,13.5 IQR) p< 0.001, with the clinical significance score in the intervention group Median= 2 (IQR 0,4) also being lower than the control group Median=11 (IQR 5,20) p< 0.001. The device was found to be technically implementable using existing IT infrastructure and acceptable to all key stakeholders. Conclusion: Medication error is a costly problem, the true extent of which may have been underestimated. Issues pertaining to communication of medication information at the primary secondary care interface were identified as contributing to the economic burden associated with medication reconciliation. In addition, it was identified that increasing time for medication reconciliation may not necessarily result cost savings in terms of reducing medication error. The intervention developed as a result of this thesis may have the potential to facilitate more efficient medication reconciliation and reduce medication error at the interface of primary and secondary care. This may result in both clinical and economic benefit. Limitations: The overall numbers of patients included in the cross-sectional and feasibility studies in this thesis are small. In addition, these studies included only older adult patients in a single geographical location and involved a single hospital

Teaching prescribing: just what the doctor ordered? A thematic analysis of the views of newly qualified doctors

Undergraduate medical education has been criticised for failing to adequately prepare doctors for the task of prescribing. Pharmacists have been shown to improve medication use in hospitals. This study aims to elicit the views of intern doctors on the challenges of prescribing, and to suggest changes in education to enhance prescribing practice and potential role of the pharmacist. Semi-structured, qualitative interviews were conducted with intern doctors in their first year post qualification in an Irish hospital. Data collection was conducted until no new themes emerged and thematic analysis was performed. Thirteen interviews took place. Interns described training in practical prescribing as limited and felt the curriculum failed to convey the reality of actual prescribing. Pharmacists were perceived to be a useful, but underutilised, information source in the prescribing process. They requested an earlier introduction, and repeated exposure, to prescribing, and suggested the involvement of peers and pharmacists in this teaching. Intern doctors reported difficulties in applying knowledge gained in medical school to clinical practice. New strategies are needed to enhance the clinical relevance of the medical curriculum by rethinking the learning outcomes regarding prescribing practice and the involvement of pharmacists in prescribing education

Cost of care for cancer patients in England: evidence from population-based patient-level data

background: Health systems are facing the challenge of providing care to an increasing population of patients with cancer. However, evidence on costs is limited due to the lack of large longitudinal databases. methods: We matched cost of care data to population-based, patient-level data on cancer patients in England. We conducted a retrospective cohort study including all patients age 18 and over with a diagnosis of colorectal (275 985 patients), breast (359 771), prostate (286 426) and lung cancer (283 940) in England between 2001 and 2010. Incidence costs, prevalence costs, and phase of care costs were estimated separately for patients age 18–64 and greater than or equal to65. Costs of care were compared by patients staging, before and after diagnosis, and with a comparison population without cancer. results: Incidence costs in the first year of diagnosis are noticeably higher in patients age 18–64 than age greater than or equal to65 across all examined cancers. A lower stage diagnosis is associated with larger cost savings for colorectal and breast cancer in both age groups. The additional costs of care because of the main four cancers amounts to £1.5 billion in 2010, namely 3.0% of the total cost of hospital care. conclusions: Population-based, patient-level data can be used to provide new evidence on the cost of cancer in England. Early diagnosis and cancer prevention have scope for achieving large cost savings for the health system

Aromatase inhibition remodels the clonal architecture of estrogen-receptor-positive breast cancers

Resistance to oestrogen-deprivation therapy is common in oestrogen-receptor-positive (ER+) breast cancer. To better understand the contributions of tumour heterogeneity and evolution to resistance, here we perform comprehensive genomic characterization of 22 primary tumours sampled before and after 4 months of neoadjuvant aromatase inhibitor (NAI) treatment. Comparing whole-genome sequencing of tumour/normal pairs from the two time points, with coincident tumour RNA sequencing, reveals widespread spatial and temporal heterogeneity, with marked remodelling of the clonal landscape in response to NAI. Two cases have genomic evidence of two independent tumours, most obviously an ER− ‘collision tumour', which was only detected after NAI treatment of baseline ER+ disease. Many mutations are newly detected or enriched post treatment, including two ligand-binding domain mutations in ESR1. The observed clonal complexity of the ER+ breast cancer genome suggests that precision medicine approaches based on genomic analysis of a single specimen are likely insufficient to capture all clinically significant information

Senescence Signatures Predict Hospitalization Risk and Severity in COVID-19 Patients

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in a global pandemic associated with substantial morbidity and mortality worldwide, with a particular risk for severe disease and mortality in the elderly population. The more aged you are the higher the risk for mortality and severity due to COVID-19. Why age is the single largest risk factor for severity in COVID-19 is not known. Together virus-induced cell senesence and aging are believed to play a central role in COVID-19 severity and pathogenesis. A deeper understanding of COVID-19 pathophysiology and the involvement of senescence/aging proteins is therefore required. This can help identify patients, at an earlier stage, who are more susceptible to acquiring a severe COVID-19 infection and those who are most likely to go on to develop post-COVID-19 syndrome. This early detection remains a major challenge however largely due to limited understanding of SARS-CoV-2 pathogenesis.In this study, we investigate whether the levels of senescence-specific plasma proteins from COVID-19 patients can be utilized to predict severity and post-COVID-19 syndrome. We performed proteomic profiling of plasma from COVID-19 patients (n = 400) using the Olink Explore 384 Inflammation Panel. Data analysis identified differences in plasma concentrations of proteins, which are linked to senescence while considering patient hospitalization status, age, and their World Health Organization (WHO) clinical progression score.The statistically significant changes were found in the senescence-associated plasma proteome of COVID-19 patients who were hospitalized, more aged, and those with severe WHO classification (TPPI, CXCL10, HGF, VEGFA, SIRPB1, IL-6, TNFRSF11B, and B4GALT1; p &lt; 0.05) and which may be linked to post-COVID-19 syndrome. Epigenetic analysis of the methylome, using the GrimAge Clock, found that biological and chronological age did not correlate in hospitalized patients. We also identified that PTX3, CXCL10, KYNU, and SIRPB1 genes had increased promoter methylation in hospitalized patients.Machine learning analysis showed that characteristic protein changes perform with a similar accuracy to that of a whole panel biomarker signature in terms of hospitalization, age, and WHO clinical progression score.This study revealed senescence specific protein changes (sendotypes) in the plasma of COVID-19 patients, which can be used as determinants for predicting COVID-19 severity, viral signature persistence, and ultimately which may lead to post-COVID-19 syndrome. We propose that the identification of such sendotypes could be exploited for therapeutic intervention via senolytics in COVID-19

Gender difference in symptomatic radiographic knee osteoarthritis in the Knee Clinical Assessment – CAS(K): A prospective study in the general population

<p>Abstract</p> <p>Background</p> <p>A recent study of adults aged ≥50 years reporting knee pain found an excess of radiographic knee osteoarthritis (knee ROA) in symptomatic males compared to females. This was independent of age, BMI and other clinical signs and symptoms. Since this finding contradicts many previous studies, our objective was to explore four possible explanations for this gender difference: X-ray views, selection, occupation and non-articular conditions.</p> <p>Methods</p> <p>A community-based prospective study. 819 adults aged ≥50 years reporting knee pain in the previous 12 months were recruited by postal questionnaires to a research clinic involving plain radiography (weight-bearing posteroanterior semiflexed, supine skyline and lateral views), clinical interview and physical examination. Any knee ROA, ROA severity, tibiofemoral joint osteoarthritis (TJOA) and patellofemoral joint osteoarthritis (PJOA) were defined using all three radiographic views. Occupational class was derived from current or last job title. Proportions of each gender with symptomatic knee ROA were expressed as percentages, stratified by age; differences between genders were expressed as percentage differences with 95% confidence intervals.</p> <p>Results</p> <p>745 symptomatic participants were eligible and had complete X-ray data. Males had a higher occurrence (77%) of any knee ROA than females (61%). In 50–64 year olds, the excess in men was mild knee OA (particularly PJOA); in ≥65 year olds, the excess was both mild and moderate/severe knee OA (particularly combined TJOA/PJOA). This male excess persisted when using the posteroanterior view only (64% vs. 52%). The lowest level of participation in the clinic was symptomatic females aged 65+. Within each occupational class there were more males with symptomatic knee ROA than females. In those aged 50–64 years, non-articular conditions were equally common in both genders although, in those aged 65+, they occurred more frequently in symptomatic females (41%) than males (31%).</p> <p>Conclusion</p> <p>The excess of knee ROA among symptomatic males in this study seems unlikely to be attributable to the use of comprehensive X-ray views. Although prior occupational exposures and the presence of non-articular conditions cannot be fully excluded, selective non-participation bias seems the most likely explanation. This has implications for future study design.</p

Thyroid Hormone Therapy for Older Adults with Subclinical Hypothyroidism.

BACKGROUND: The use of levothyroxine to treat subclinical hypothyroidism is controversial. We aimed to determine whether levothyroxine provided clinical benefits in older persons with this condition. METHODS: We conducted a double-blind, randomized, placebo-controlled, parallel-group trial involving 737 adults who were at least 65 years of age and who had persisting subclinical hypothyroidism (thyrotropin level, 4.60 to 19.99 mIU per liter; free thyroxine level within the reference range). A total of 368 patients were assigned to receive levothyroxine (at a starting dose of 50 μg daily, or 25 μg if the body weight was <50 kg or the patient had coronary heart disease), with dose adjustment according to the thyrotropin level; 369 patients were assigned to receive placebo with mock dose adjustment. The two primary outcomes were the change in the Hypothyroid Symptoms score and Tiredness score on a thyroid-related quality-of-life questionnaire at 1 year (range of each scale is 0 to 100, with higher scores indicating more symptoms or tiredness, respectively; minimum clinically important difference, 9 points). RESULTS: The mean age of the patients was 74.4 years, and 396 patients (53.7%) were women. The mean (±SD) thyrotropin level was 6.40±2.01 mIU per liter at baseline; at 1 year, this level had decreased to 5.48 mIU per liter in the placebo group, as compared with 3.63 mIU per liter in the levothyroxine group (P<0.001), at a median dose of 50 μg. We found no differences in the mean change at 1 year in the Hypothyroid Symptoms score (0.2±15.3 in the placebo group and 0.2±14.4 in the levothyroxine group; between-group difference, 0.0; 95% confidence interval [CI], -2.0 to 2.1) or the Tiredness score (3.2±17.7 and 3.8±18.4, respectively; between-group difference, 0.4; 95% CI, -2.1 to 2.9). No beneficial effects of levothyroxine were seen on secondary-outcome measures. There was no significant excess of serious adverse events prespecified as being of special interest. CONCLUSIONS: Levothyroxine provided no apparent benefits in older persons with subclinical hypothyroidism. (Funded by European Union FP7 and others; TRUST ClinicalTrials.gov number, NCT01660126 .)

Whole-Exome Sequencing and Homozygosity Analysis Implicate Depolarization-Regulated Neuronal Genes in Autism

Although autism has a clear genetic component, the high genetic heterogeneity of the disorder has been a challenge for the identification of causative genes. We used homozygosity analysis to identify probands from nonconsanguineous families that showed evidence of distant shared ancestry, suggesting potentially recessive mutations. Whole-exome sequencing of 16 probands revealed validated homozygous, potentially pathogenic recessive mutations that segregated perfectly with disease in 4/16 families. The candidate genes (UBE3B, CLTCL1, NCKAP5L, ZNF18) encode proteins involved in proteolysis, GTPase-mediated signaling, cytoskeletal organization, and other pathways. Furthermore, neuronal depolarization regulated the transcription of these genes, suggesting potential activity-dependent roles in neurons. We present a multidimensional strategy for filtering whole-exome sequence data to find candidate recessive mutations in autism, which may have broader applicability to other complex, heterogeneous disorders

Antimicrobial resistance among migrants in Europe: a systematic review and meta-analysis

BACKGROUND: Rates of antimicrobial resistance (AMR) are rising globally and there is concern that increased migration is contributing to the burden of antibiotic resistance in Europe. However, the effect of migration on the burden of AMR in Europe has not yet been comprehensively examined. Therefore, we did a systematic review and meta-analysis to identify and synthesise data for AMR carriage or infection in migrants to Europe to examine differences in patterns of AMR across migrant groups and in different settings. METHODS: For this systematic review and meta-analysis, we searched MEDLINE, Embase, PubMed, and Scopus with no language restrictions from Jan 1, 2000, to Jan 18, 2017, for primary data from observational studies reporting antibacterial resistance in common bacterial pathogens among migrants to 21 European Union-15 and European Economic Area countries. To be eligible for inclusion, studies had to report data on carriage or infection with laboratory-confirmed antibiotic-resistant organisms in migrant populations. We extracted data from eligible studies and assessed quality using piloted, standardised forms. We did not examine drug resistance in tuberculosis and excluded articles solely reporting on this parameter. We also excluded articles in which migrant status was determined by ethnicity, country of birth of participants' parents, or was not defined, and articles in which data were not disaggregated by migrant status. Outcomes were carriage of or infection with antibiotic-resistant organisms. We used random-effects models to calculate the pooled prevalence of each outcome. The study protocol is registered with PROSPERO, number CRD42016043681. FINDINGS: We identified 2274 articles, of which 23 observational studies reporting on antibiotic resistance in 2319 migrants were included. The pooled prevalence of any AMR carriage or AMR infection in migrants was 25·4% (95% CI 19·1-31·8; I2 =98%), including meticillin-resistant Staphylococcus aureus (7·8%, 4·8-10·7; I2 =92%) and antibiotic-resistant Gram-negative bacteria (27·2%, 17·6-36·8; I2 =94%). The pooled prevalence of any AMR carriage or infection was higher in refugees and asylum seekers (33·0%, 18·3-47·6; I2 =98%) than in other migrant groups (6·6%, 1·8-11·3; I2 =92%). The pooled prevalence of antibiotic-resistant organisms was slightly higher in high-migrant community settings (33·1%, 11·1-55·1; I2 =96%) than in migrants in hospitals (24·3%, 16·1-32·6; I2 =98%). We did not find evidence of high rates of transmission of AMR from migrant to host populations. INTERPRETATION: Migrants are exposed to conditions favouring the emergence of drug resistance during transit and in host countries in Europe. Increased antibiotic resistance among refugees and asylum seekers and in high-migrant community settings (such as refugee camps and detention facilities) highlights the need for improved living conditions, access to health care, and initiatives to facilitate detection of and appropriate high-quality treatment for antibiotic-resistant infections during transit and in host countries. Protocols for the prevention and control of infection and for antibiotic surveillance need to be integrated in all aspects of health care, which should be accessible for all migrant groups, and should target determinants of AMR before, during, and after migration. FUNDING: UK National Institute for Health Research Imperial Biomedical Research Centre, Imperial College Healthcare Charity, the Wellcome Trust, and UK National Institute for Health Research Health Protection Research Unit in Healthcare-associated Infections and Antimictobial Resistance at Imperial College London

Genome-wide association of familial prostate cancer cases identifies evidence for a rare segregating haplotype at 8q24.21

Previous genome-wide association studies (GWAS) of prostate cancer risk focused on cases unselected for family history and have reported over 100 significant associations. The International Consortium for Prostate Cancer Genetics (ICPCG) has now performed a GWAS of 2511 (unrelated) familial prostate cancer cases and 1382 unaffected controls from 12 member sites. All samples were genotyped on the Illumina 5M+exome single nucleotide polymorphism (SNP) platform. The GWAS identified a significant evidence for association for SNPs in six regions previously associated with prostate cancer in population-based cohorts, including 3q26.2, 6q25.3, 8q24.21, 10q11.23, 11q13.3, and 17q12. Of note, SNP rs138042437 (p = 1.7e−8) at 8q24.21 achieved a large estimated effect size in this cohort (odds ratio = 13.3). 116 previously sampled affected relatives of 62 risk-allele carriers from the GWAS cohort were genotyped for this SNP, identifying 78 additional affected carriers in 62 pedigrees. A test for an excess number of affected carriers among relatives exhibited strong evidence for co-segregation of the variant with disease (p = 8.5e−11). The majority (92 %) of risk-allele carriers at rs138042437 had a consistent estimated haplotype spanning approximately 100 kb of 8q24.21 that contained the minor alleles of three rare SNPs (dosage minor allele frequencies <1.7 %), rs183373024 (PRNCR1), previously associated SNP rs188140481, and rs138042437 (CASC19). Strong evidence for co-segregation of a SNP on the haplotype further characterizes the haplotype as a prostate cancer pre-disposition locus